Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models

[1]  J. Pennings,et al.  Cyclosporine A treated in vitro models induce cholestasis response through comparison of phenotype-directed gene expression analysis of in vivo Cyclosporine A-induced cholestasis. , 2013, Toxicology letters.

[2]  Michael J. Thomas,et al.  High Density Lipoprotein Biogenesis, Cholesterol Efflux, and Immune Cell Function , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[3]  H. Yamada,et al.  Evaluation of DNA microarray results in the Toxicogenomics Project (TGP) consortium in Japan. , 2012, The Journal of toxicological sciences.

[4]  C. Argmann,et al.  Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids , 2012, Journal of Lipid Research.

[5]  G. Fuchs,et al.  Dietary soy protein induces hepatic lipogenic enzyme gene expression while suppressing hepatosteatosis in obese female Zucker rats bearing DMBA-initiated mammary tumors , 2012, Genes & Nutrition.

[6]  J. Burkhardt,et al.  Examining the safety of amiodarone , 2012, Expert opinion on drug safety.

[7]  W. Jeong,et al.  Retinoic acids and hepatic stellate cells in liver disease , 2012, Journal of gastroenterology and hepatology.

[8]  Craig E Thomas,et al.  The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery , 2012, Expert opinion on drug discovery.

[9]  A. Palou,et al.  Lipid metabolism in mammalian tissues and its control by retinoic acid. , 2012, Biochimica et biophysica acta.

[10]  Michael Müller,et al.  Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice. , 2011, Physiological genomics.

[11]  J. Pennings,et al.  Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa-/-p53+/- mice upon exposure to benzo[a]pyrene. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[13]  D. Amacher.  The mechanistic basis for the induction of hepatic steatosis by xenobiotics , 2011, Expert opinion on drug metabolism & toxicology.

[14]  V. Navarro,et al.  Review article: drug‐induced liver injury – its pathophysiology and evolving diagnostic tools , 2011, Alimentary pharmacology & therapeutics.

[15]  M. Trauner,et al.  Nuclear receptors in liver disease , 2011, Hepatology.

[16]  W. Blaner,et al.  Vitamin A Metabolism: An Update , 2011, Nutrients.

[17]  Michael Müller,et al.  Peroxisome Proliferator-Activated Receptor Alpha Target Genes , 2010, PPAR research.

[18]  Matej Oresic,et al.  Peroxisomal and Microsomal Lipid Pathways Associated with Resistance to Hepatic Steatosis and Reduced Pro-inflammatory State* , 2010, The Journal of Biological Chemistry.

[19]  Joaquín Dopazo,et al.  Babelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling , 2010, Nucleic Acids Res..

[20]  H. Yamada,et al.  The Japanese toxicogenomics project: application of toxicogenomics. , 2010, Molecular nutrition & food research.

[21]  W. Graninger,et al.  Hepatotoxicity of Antibacterials: Pathomechanisms and Clinical Data , 2010, Infection.

[22]  André Boorsma,et al.  Parallelogram approach using rat-human in vitro and rat in vivo toxicogenomics predicts acetaminophen-induced hepatotoxicity in humans. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[24]  N. Anderson,et al.  Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis , 2008, Pharmacological Reviews.

[25]  P. Olinga,et al.  Microarray analysis in rat liver slices correctly predicts in vivo hepatotoxicity. , 2008, Toxicology and applied pharmacology.

[26]  J. Hardwick.  Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. , 2008, Biochemical pharmacology.

[27]  S. Yeh,et al.  Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor , 2008, Hepatology.

[28]  M. Duran,et al.  Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review , 2008, Journal of Inherited Metabolic Disease.

[29]  K. Hoffmaster,et al.  Current in vitro Models to Study Drug‐Induced Liver Injury , 2008 .

[30]  G. Kong,et al.  Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. , 2008, Toxicology and applied pharmacology.

[31]  Liming Pei,et al.  Nuclear receptors: Decoding metabolic disease , 2008, FEBS letters.

[32]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[33]  M. Miyazaki,et al.  Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. , 2007, Cell metabolism.

[34]  G. Kong,et al.  Gene expression profiles of murine fatty liver induced by the administration of valproic acid. , 2007, Toxicology and applied pharmacology.

[35]  Khalid Raza,et al.  GENE EXPRESSION PROFILES , 2007 .

[36]  G. Kong,et al.  Hepatic gene expression profiling and lipid homeostasis in mice exposed to steatogenic drug, tetracycline. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[37]  Christopher J Sinal,et al.  Disruption of Hepatic Lipid Homeostasis in Mice after Amiodarone Treatment Is Associated with Peroxisome Proliferator-Activated Receptor-αTarget Gene Activation , 2004, Journal of Pharmacology and Experimental Therapeutics.

[38]  M. Reitman,et al.  Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.

[39]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[40]  Wout Slob,et al.  Dose-response modeling of continuous endpoints. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[41]  G. Gores,et al.  Mechanisms of hepatotoxicity. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  Stephen H. Friend,et al.  Toxicogenomics and drug discovery: will new technologies help us produce better drugs? , 2002, Nature Reviews Drug Discovery.

[43]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[44]  M. Rice,et al.  Disruption of muREC2/RAD51L1 in Mice Results in Early Embryonic Lethality Which Can Be Partially Rescued in a p53−/− Background , 1999, Molecular and Cellular Biology.

[45]  H. Zimmerman,et al.  Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .